메뉴 건너뛰기




Volumn 6, Issue MAR, 2014, Pages

The many questions on the use of biomarkers for neurodegenerative diseases in clinical practice

Author keywords

Biomarker; Clinical practice; Dementia; Mild cognitive impairment; Treatment outcome

Indexed keywords

BIOLOGICAL MARKER;

EID: 84898033416     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2014.00045     Document Type: Article
Times cited : (4)

References (6)
  • 1
    • 79956084514 scopus 로고    scopus 로고
    • The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
    • doi: 10.1016/j.jalz.2011.03.008
    • Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., et al. (2011). The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 270-279. doi: 10.1016/j.jalz.2011.03.008
    • (2011) Alzheimers Dement , vol.7 , pp. 270-279
    • Albert, M.S.1    DeKosky, S.T.2    Dickson, D.3    Dubois, B.4    Feldman, H.H.5    Fox, N.C.6
  • 2
    • 84878223127 scopus 로고    scopus 로고
    • Translational outpatient memory clinic working group. Supporting evidence for using biomarkers in the diagnosis of MCI due to AD
    • doi: 10.1007/s00415-012-6694-0
    • Galluzzi, S., Geroldi, C., Amicucci, G., Bocchio-Chiavetto, L., Bonetti, M., Bonvicini, C., et al. (2013). Translational outpatient memory clinic working group. Supporting evidence for using biomarkers in the diagnosis of MCI due to AD. J. Neurol. 260, 640-650. doi: 10.1007/s00415-012-6694-0
    • (2013) J. Neurol. , vol.260 , pp. 640-650
    • Galluzzi, S.1    Geroldi, C.2    Amicucci, G.3    Bocchio-Chiavetto, L.4    Bonetti, M.5    Bonvicini, C.6
  • 3
    • 82955198535 scopus 로고    scopus 로고
    • Alzheimer's disease neuroimaging initiative. Predicting MCI outcome with clinically available MRI and CSF biomarkers
    • doi: 10.1212/WNL.0b013e3182343314
    • Heister, D., Brewer, J. B., Magda, S., Blennow, K., and McEvoy, L. K. (2011). Alzheimer's disease neuroimaging initiative. Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology 77, 1619-1628. doi: 10.1212/WNL.0b013e3182343314
    • (2011) Neurology , vol.77 , pp. 1619-1628
    • Heister, D.1    Brewer, J.B.2    Magda, S.3    Blennow, K.4    McEvoy, L.K.5
  • 5
    • 79956098248 scopus 로고    scopus 로고
    • Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
    • doi: 10.1016/j.jalz.2011.03.003
    • Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., et al. (2011). Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 280-292. doi: 10.1016/j.jalz.2011.03.003
    • (2011) Alzheimers Dement , vol.7 , pp. 280-292
    • Sperling, R.A.1    Aisen, P.S.2    Beckett, L.A.3    Bennett, D.A.4    Craft, S.5    Fagan, A.M.6
  • 6
    • 84898042082 scopus 로고    scopus 로고
    • Alzheimer'CSF test: useful or useless?
    • Wilner, A. N. (2010). Alzheimer'CSF test: useful or useless? Medscape.
    • (2010) Medscape
    • Wilner, A.N.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.